Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Keats, Emily C ^a   Khan, Zia A ^a,b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c 4011 Dental Sciences Building ^*  (Canada)

Author keywords

Angiogenesis; Angiopathy; Diabetes; Diabetic complications; Endothelial cells; Perivascular cells; Progenitors; Stem cells; Vasculogenesis

Indexed keywords

BETA1 INTEGRIN; CALPONIN; CD133 ANTIGEN; CD14 ANTIGEN; CD146 ANTIGEN; CD31 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; ENDOGLIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GLUCOSE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN A;

ADIPOCYTE; ATHEROSCLEROSIS; CARTILAGE CELL; CELL EXPANSION; CELL INTERACTION; CELL LOSS; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL THERAPY; DIABETIC ANGIOPATHY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GLUCOSE TRANSPORT; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; MESENCHYMAL STEM CELL; NONHUMAN; OSTEOCYTE; OXIDATION REDUCTION STATE; PATHOGENESIS; PERICYTE; REVIEW; STEM CELL; VASCULAR ENDOTHELIUM; VASCULAR STEM CELL; VASODILATATION;

ANIMALS; BLOOD GLUCOSE; DIABETIC ANGIOPATHIES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MUSCLE, SMOOTH, VASCULAR; NEOVASCULARIZATION, PHYSIOLOGIC; REGENERATION; TREATMENT OUTCOME;

EID: 84865714353     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-37     Document Type: Review

References (92)

1. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997, 14(Suppl 5):S1-S85.
2. An economic tsunami, the cost of diabetes in Canada. Book An economic tsunami, the cost of diabetes in Canada 2009, , , (Editor ed.^eds.). City: Canadian Diabetes Association.
3. 2011 National Diabetes Fact Sheet, National Center for Chronic Disease Prevention and Health Promotion. Book 2011 National Diabetes Fact Sheet, National Center for Chronic Disease Prevention and Health Promotion 2011, , , (Editor ed.^eds.), vol. 2011. City: American Diabetes Association.
4. King H, Rewers M. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. WHO Ad Hoc Diabetes Reporting Group. Diabetes Care 1993, 16:157-177. 10.2337/diacare.16.1.157, 8123057.
5. Engerman R, Bloodworth JM, Nelson S. Relationship of microvascular disease in diabetes to metabolic control. Diabetes 1977, 26:760-769. 10.2337/diabetes.26.8.760, 885298.
6. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 33:1090-1096.
7. Ratner RE. Glycemic control in the prevention of diabetic complications. Clin Cornerstone 2001, 4:24-37. 10.1016/S1098-3597(01)90027-4, 11838325.
8. Florey. The endothelial cell. Br Med J 1966, 2:487-490. 10.1136/bmj.2.5512.487, 1943522, 5913081.
9. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
10. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members (review). Mol Membr Biol 2001, 18:247-256. 10.1080/09687680110090456, 11780753.
11. Augustin R. The protein family of glucose transport facilitators: Its not only about glucose after all. IUBMB Life 62:315-333.
12. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol Endocrinol Metab 298:E141-E145.
13. Mandarino LJ, Finlayson J, Hassell JR. High glucose downregulates glucose transport activity in retinal capillary pericytes but not endothelial cells. Invest Ophthalmol Vis Sci 1994, 35:964-972.
14. Kaiser N, Sasson S, Feener EP, Boukobza-Vardi N, Higashi S, Moller DE, Davidheiser S, Przybylski RJ, King GL. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993, 42:80-89. 10.2337/diabetes.42.1.80, 7678404.
15. Wertheimer E, Sasson S, Cerasi E, Ben-Neriah Y. The ubiquitous glucose transporter GLUT-1 belongs to the glucose-regulated protein family of stress-inducible proteins. Proc Natl Acad Sci U S A 1991, 88:2525-2529. 10.1073/pnas.88.6.2525, 51265, 1706526.
16. Takagi H, King GL, Aiello LP. Hypoxia upregulates glucose transport activity through an adenosine-mediated increase of GLUT1 expression in retinal capillary endothelial cells. Diabetes 1998, 47:1480-1488. 10.2337/diabetes.47.9.1480, 9726238.
17. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820. 10.1038/414813a, 11742414.
18. Khan ZA, Chakrabarti S. Therapeutic targeting of endothelial dysfunction in chronic diabetic complications. Recent Pat Cardiovasc Drug Discov 2006, 1:167-175. 10.2174/157489006777442531, 18221084.
19. Khan ZA, Farhangkhoee H, Mahon JL, Bere L, Gonder JR, Chan BM, Uniyal S, Chakrabarti S. Endothelins: regulators of extracellular matrix protein production in diabetes. Exp Biol Med (Maywood) 2006, 231:1022-1029.
20. Cagliero E, Maiello M, Boeri D, Roy S, Lorenzi M. Increased expression of basement membrane components in human endothelial cells cultured in high glucose. J Clin Invest 1988, 82:735-738. 10.1172/JCI113655, 303571, 3403725.
21. Graier WF, Grubenthal I, Dittrich P, Wascher TC, Kostner GM. Intracellular mechanism of high D-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 1995, 294:221-229. 10.1016/0014-2999(95)00534-X, 8788435.
22. Du XL, Sui GZ, Stockklauser-Farber K, Weiss J, Zink S, Schwippert B, Wu QX, Tschope D, Rosen P. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia 1998, 41:249-256. 10.1007/s001250050900, 9541163.
23. Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985, 34:621-627. 10.2337/diabetes.34.7.621, 3924693.
24. Baumgartner-Parzer SM, Wagner L, Pettermann M, Grillari J, Gessl A, Waldhausl W. High-glucosetriggered apoptosis in cultured endothelial cells. Diabetes 1995, 44:1323-1327. 10.2337/diabetes.44.11.1323, 7589831.
25. Yang Z, Mo X, Gong Q, Pan Q, Yang X, Cai W, Li C, Ma JX, He Y, Gao G. Critical effect of VEGF in the process of endothelial cell apoptosis induced by high glucose. Apoptosis 2008, 13:1331-1343. 10.1007/s10495-008-0257-y, 18780185.
26. Favaro E, Miceli I, Bussolati B, Schmitt-Ney M, Cavallo Perin P, Camussi G, Zanone MM. Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway. Am J Pathol 2008, 173:442-450. 10.2353/ajpath.2008.080238, 2475781, 18599614.
27. Chen S, Khan ZA, Barbin Y, Chakrabarti S. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004, 38:1301-1310. 10.1080/10715760400017228, 15763954.
28. El-Remessy AB, Abou-Mohamed G, Caldwell RW, Caldwell RB. High glucose-induced tyrosine nitration in endothelial cells: role of eNOS uncoupling and aldose reductase activation. Invest Ophthalmol Vis Sci 2003, 44:3135-3143. 10.1167/iovs.02-1022, 12824263.
29. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, Yorek MA, Beebe D, Oates PJ, Hammes HP, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000, 404:787-790. 10.1038/35008121, 10783895.
30. van den Oever IA, Raterman HG, Nurmohamed MT, Simsek S. Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus. Mediators Inflamm 2010, 792393.
31. Aronson D. Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 2008, 45:1-16.
32. Alberti KG, Zimmet PZ. New diagnostic criteria and classification of diabetesagain?. Diabet Med 1998, 15:535-536. 10.1002/(SICI)1096-9136(199807)15:7<535::AID-DIA670>3.0.CO;2-Q, 9686691.
33. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, Suzuma K, Bowling NL, Vlahos CJ, Aiello LP, King GL. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation 2002, 105:373-379. 10.1161/hc0302.102143, 11804995.
34. Khan ZA, Chakrabarti S. Growth factors in proliferative diabetic retinopathy. Exp Diabesity Res 2003, 4:287-301. 10.1155/EDR.2003.287, 2478606, 14668050.
35. Boudreau NJ, Jones PL. Extracellular matrix and integrin signalling: the shape of things to come. Biochem J 1999, 339(Pt 3):481-488. 1220180, 10215583.
36. Jiang B, Liou GI, Behzadian MA, Caldwell RB. Astrocytes modulate retinal vasculogenesis: effects on fibronectin expression. J Cell Sci 1994, 107(Pt 9):2499-2508.
37. Nishikawa T, Giardino I, Edelstein D, Brownlee M. Changes in diabetic retinal matrix protein mRNA levels in a common transgenic mouse strain. Curr Eye Res 2000, 21:581-587. 10.1076/0271-3683(200007)2111-ZFT581, 11035540.
38. Katwa LC, Guarda E, Weber KT. Endothelin receptors in cultured adult rat cardiac fibroblasts. Cardiovasc Res 1993, 27:2125-2129. 10.1093/cvr/27.12.2125, 8313418.
39. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993, 27:2130-2134. 10.1093/cvr/27.12.2130, 8313419.
40. Chandrasekhar KS, Zhou H, Zeng P, Alge D, Li W, Finney BA, Yoder MC, Li J. Blood vessel wall-derived endothelial colony-forming cells enhance fracture repair and bone regeneration. Calcif Tissue Int 2011, 89:347-357. 10.1007/s00223-011-9524-y, 21882012.
41. Wu Y, Wang J, Scott PG, Tredget EE. Bone marrow-derived stem cells in wound healing: a review. Wound Repair Regen 2007, 15(Suppl 1):S18-S26.
42. Tepper OM, Galiano RD, Kalka C, Gurtner GC. Endothelial progenitor cells: the promise of vascular stem cells for plastic surgery. Plast Reconstr Surg 2003, 111:846-854. 10.1097/01.PRS.0000039576.63523.08, 12560713.
43. Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13:4279-4295. 10.1091/mbc.E02-02-0105, 138633, 12475952.
44. Kattman SJ, Huber TL, Keller GM. Multipotent flk-1+ cardiovascular progenitor cells give rise to the cardiomyocyte, endothelial, and vascular smooth muscle lineages. Dev Cell 2006, 11:723-732. 10.1016/j.devcel.2006.10.002, 17084363.
45. Yamashita J, Itoh H, Hirashima M, Ogawa M, Nishikawa S, Yurugi T, Naito M, Nakao K. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature 2000, 408:92-96. 10.1038/35040568, 11081514.
46. Ferreira LS, Gerecht S, Shieh HF, Watson N, Rupnick MA, Dallabrida SM, Vunjak-Novakovic G, Langer R. Vascular progenitor cells isolated from human embryonic stem cells give rise to endothelial and smooth muscle like cells and form vascular networks in vivo. Circ Res 2007, 101:286-294. 10.1161/CIRCRESAHA.107.150201, 17569886.
47. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, Mulliken JB, Bischoff J. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 2008, 118:2592-2599. 2413184, 18535669.
48. Khan ZA, Melero-Martin JM, Wu X, Paruchuri S, Boscolo E, Mulliken JB, Bischoff J. Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 2006, 108:915-921. 10.1182/blood-2006-03-006478, 1895853, 16861344.
49. Wu X, Rabkin-Aikawa E, Guleserian KJ, Perry TE, Masuda Y, Sutherland FW, Schoen FJ, Mayer JE, Bischoff J. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2004, 287:H480-H487. 10.1152/ajpheart.01232.2003, 15277191.
50. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000, 95:952-958.
51. Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, Mortier C, Bron D, Lagneaux L. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: proliferation, Oct4 expression, and plasticity. Stem Cells 2005, 23:1105-1112. 10.1634/stemcells.2004-0330, 15955825.
52. Melero-Martin JM, De Obaldia ME, Kang SY, Khan ZA, Yuan L, Oettgen P, Bischoff J. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res 2008, 103:194-202. 10.1161/CIRCRESAHA.108.178590, 2746761, 18556575.
53. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood 2007, 109:4761-4768. 10.1182/blood-2006-12-062471, 17327403.
54. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, Bhavsar JR, Yoder MC, Haneline LS, Ingram DA. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007, 35:1109-1118. 10.1016/j.exphem.2007.04.002, 17588480.
55. Zampetaki A, Kirton JP, Xu Q. Vascular repair by endothelial progenitor cells. Cardiovasc Res 2008, 78:413-421. 10.1093/cvr/cvn081, 18349136.
56. Fadini GP, Agostini C, Avogaro A. Characterization of endothelial progenitor cells. Biochem Biophys Res Commun 2005, 336:1-2. 10.1016/j.bbrc.2005.07.119, 16084490.
57. Lopez-Holgado N, Alberca M, Sanchez-Guijo F, Villaron E, Almeida J, Martin A, Armellini A, Garcia C, Blanco B, Sanchez-Abarca I, et al. Short-term endothelial progenitor cell colonies are composed of monocytes and do not acquire endothelial markers. Cytotherapy 2007, 9:14-22. 10.1080/14653240601047726, 17354099.
58. Capla JM, Grogan RH, Callaghan MJ, Galiano RD, Tepper OM, Ceradini DJ, Gurtner GC. Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast Reconstr Surg 2007, 119:59-70. 10.1097/01.prs.0000244830.16906.3f, 17255657.
59. Kusuyama T, Omura T, Nishiya D, Enomoto S, Matsumoto R, Takeuchi K, Yoshikawa J, Yoshiyama M. Effects of treatment for diabetes mellitus on circulating vascular progenitor cells. J Pharmacol Sci 2006, 102:96-102. 10.1254/jphs.FP0060256, 16990702.
60. Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, Wang SY, Hung A, Cherng WJ. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 2006, 152:e1051-e1058.
61. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A 1979, 76:333-337. 10.1073/pnas.76.1.333, 382933, 218198.
62. Jackson CJ, Garbett PK, Nissen B, Schrieber L. Binding of human endothelium to Ulex europaeus I-coated Dynabeads: application to the isolation of microvascular endothelium. J Cell Sci 1990, 96(Pt 2):257-262.
63. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809. 10.1182/blood-2006-08-043471, 1801067, 17053059.
64. Bernardi S, Severini GM, Zauli G, Secchiero P. Cell-based therapies for diabetic complications. Exp Diabetes Res 2012, 2012:872504. 3123995, 21822425.
65. Loomans CJ, de Koning EJ, Staal FJ, Rookmaaker MB, Verseyden C, de Boer HC, Verhaar MC, Braam B, Rabelink TJ, van Zonneveld AJ. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004, 53:195-199.
66. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7. 10.1161/hh1301.093953, 11440984.
67. Fadini GP, Sartore S, Albiero M, Baesso I, Murphy E, Menegolo M, Grego F, Vigili de Kreutzenberg S, Tiengo A, Agostini C, Avogaro A. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006, 26:2140-2146. 10.1161/01.ATV.0000237750.44469.88, 16857948.
68. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, Grego F, Menegolo M, de Kreutzenberg SV, Tiengo A, Agostini C, Avogaro A. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005, 45:1449-1457. 10.1016/j.jacc.2004.11.067, 15862417.
69. Yue WS, Lau KK, Siu CW, Wang M, Yan GH, Yiu KH, Tse HF. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 2011, 10:113. 10.1186/1475-2840-10-113, 3258289, 22185563.
70. Bozdag-Turan I, Turan RG, Turan CH, Ludovicy S, Akin I, Kische S, Arsoy NS, Schneider H, Ortak J, Rehders T, et al. Relation between the frequency of CD34 bone marrow derived circulating progenitor cells and the number of diseased coronary arteries in patients with myocardial ischemia and diabetes. Cardiovasc Diabetol 2011, 10:107. 10.1186/1475-2840-10-107, 3235974, 22118372.
71. Tamarat R, Silvestre JS, Le Ricousse-Roussanne S, Barateau V, Lecomte-Raclet L, Clergue M, Duriez M, Tobelem G, Levy BI. Impairment in ischemia-induced neovascularization in diabetes: bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. Am J Pathol 2004, 164:457-466. 10.1016/S0002-9440(10)63136-7, 1602274, 14742252.
72. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002, 106:2781-2786. 10.1161/01.CIR.0000039526.42991.93, 12451003.
73. Keats E, Khan ZA. High glucose causes impairment of mature endothelial cells but not adult endothelial progenitor cells. Can J Diabetes 2011, 35:A126.
74. Keats E, Khan ZA. Unique cellular responses of adult blood-derived endothelial progenitor cells and mature endothelial cells to high glucose. Diabetes 2011, 60:1624. 10.2337/db10-1656, 3292339, 21441443.
75. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147. 10.1126/science.284.5411.143, 10102814.
76. Campagnoli C, Roberts IA, Kumar S, Bennett PR, Bellantuono I, Fisk NM. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98:2396-2402. 10.1182/blood.V98.8.2396, 11588036.
77. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, Johnstone BH, March KL. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 2008, 102:77-85. 10.1161/CIRCRESAHA.107.159475, 17967785.
78. Zhang N, Li J, Luo R, Jiang J, Wang JA. Bone marrow mesenchymal stem cells induce angiogenesis and attenuate the remodeling of diabetic cardiomyopathy. Exp Clin Endocrinol Diabetes 2008, 116:104-111. 10.1055/s-2007-985154, 18286426.
79. Ezquer FE, Ezquer ME, Parrau DB, Carpio D, Yanez AJ, Conget PA. Systemic administration of multipotent mesenchymal stromal cells reverts hyperglycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 2008, 14:631-640. 10.1016/j.bbmt.2008.01.006, 18489988.
80. Lee RH, Seo MJ, Reger RL, Spees JL, Pulin AA, Olson SD, Prockop DJ. Multipotent stromal cells from human marrow home to and promote repair of pancreatic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci U S A 2006, 103:17438-17443. 10.1073/pnas.0608249103, 1634835, 17088535.
81. Shibata T, Naruse K, Kamiya H, Kozakae M, Kondo M, Yasuda Y, Nakamura N, Ota K, Tosaki T, Matsuki T, et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008, 57:3099-3107. 10.2337/db08-0031, 2570407, 18728233.
82. Kuo YR, Wang CT, Cheng JT, Wang FS, Chiang YC, Wang CJ. Bone marrow-derived mesenchymal stem cells enhanced diabetic wound healing through recruitment of tissue regeneration in a rat model of streptozotocin-induced diabetes. Plast Reconstr Surg 2011, 128:872-880. 10.1097/PRS.0b013e3182174329, 21921763.
83. Yang K, Wang XQ, He YS, Lu L, Chen QJ, Liu J, Shen WF. Advanced glycation end products induce chemokine/cytokine production via activation of p38 pathway and inhibit proliferation and migration of bone marrow mesenchymal stem cells. Cardiovasc Diabetol 2010, 9:66. 10.1186/1475-2840-9-66, 2987998, 20969783.
84. Falanga V, Iwamoto S, Chartier M, Yufit T, Butmarc J, Kouttab N, Shrayer D, Carson P. Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds. Tissue Eng 2007, 13:1299-1312. 10.1089/ten.2006.0278, 17518741.
85. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007, 25:2648-2659. 10.1634/stemcells.2007-0226, 17615264.
86. Javazon EH, Keswani SG, Badillo AT, Crombleholme TM, Zoltick PW, Radu AP, Kozin ED, Beggs K, Malik AA, Flake AW. Enhanced epithelial gap closure and increased angiogenesis in wounds of diabetic mice treated with adult murine bone marrow stromal progenitor cells. Wound Repair Regen 2007, 15:350-359. 10.1111/j.1524-475X.2007.00237.x, 17537122.
87. Naruse K, Hamada Y, Nakashima E, Kato K, Mizubayashi R, Kamiya H, Yuzawa Y, Matsuo S, Murohara T, Matsubara T, et al. Therapeutic neovascularization using cord blood-derived endothelial progenitor cells for diabetic neuropathy. Diabetes 2005, 54:1823-1828. 10.2337/diabetes.54.6.1823, 15919805.
88. Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005, 28:2155-2160. 10.2337/diacare.28.9.2155, 16123483.
89. Koike N, Fukumura D, Gralla O, Au P, Schechner JS, Jain RK. Tissue engineering: creation of long-lasting blood vessels. Nature 2004, 428:138-139. 10.1038/428138a, 15014486.
90. Nor JE, Peters MC, Christensen JB, Sutorik MM, Linn S, Khan MK, Addison CL, Mooney DJ, Polverini PJ. Engineering and characterization of functional human microvessels in immunodeficient mice. Lab Invest 2001, 81:453-463. 10.1038/labinvest.3780253, 11304564.
91. Au P, Daheron LM, Duda DG, Cohen KS, Tyrrell JA, Lanning RM, Fukumura D, Scadden DT, Jain RK. Differential in vivo potential of endothelial progenitor cells from human umbilical cord blood and adult peripheral blood to form functional long-lasting vessels. Blood 2008, 111:1302-1305. 2214740, 17993613.
92. Simper D, Stalboerger PG, Panetta CJ, Wang S, Caplice NM. Smooth muscle progenitor cells in human blood. Circulation 2002, 106:1199-1204. 10.1161/01.CIR.0000031525.61826.A8, 12208793.